New from Hobart and our companies

Motorika and ORIGIN Polska Launch New Strategic Partnership to Enhance Rehabilitation Care in Poland

Hamilton, Bermuda, August 13, 2018

Motorika’s cutting-edge robotic rehabilitation solutions to be installed in ORIGIN Polska’s state-of-the-art rehab centers in Poland.

Read more

EPD obtains European regulatory approval for its Cardiac Mapping and Navigation System

Tortola, BVI, February 26, 2018

EPD’s Cardiac Mapping and Navigation System received CE mark approval.  The system helps electrophysiologists navigate the heart by generating an accurate 3D map, while imaging and pinpointing the exact location and orientation of catheters in the heart during diagnostic and therapeutic procedures for cardiac arrhythmias. “Receiving the CE mark is a very significant milestone for […]

Read more

Impulse Dynamics Announces First US Implant in the FIX-HF-5CA Continued Access Study

Orangeburg, New York. August 8, 2017

Impulse Dynamics announced today the first implant in the Company’s FIX-HF-5CA Continued Access Study. The FIX-HF-5CA study is a multicenter, prospective, single-arm continued access evaluation of the company’s Cardiac Contractility Modulation (CCM) device. Impulse Dynamics’ proprietary CCM technology delivers non-excitatory electric pulses to the cardiac muscle, with the potential for improved exercise capacity and quality of life.

Read more

Randomization of the FIX-HF-5C Confirmatory Study Completed

Orangeburg, New York, March 31, 2017

Impulse Dynamics is pleased to announce that it has successfully completed enrollment of the 160 subjects required for its FIX-HF-5C Confirmatory Study. The FIX-HF-5C Study is a prospective, multicenter, randomized study to evaluate the safety and efficacy of cardiac contractility modulation (CCM) signals delivered by the implantable Optimizer System in patients with NYHA class III […]

Read more

DURABLE-I ground-breaking clinical study results presented at the 2017 AF Symposium

Orlando, January 31 2017

Results from EPD’s DURABLE-I clinical trial, whose principal investigator is Professor Evgeny A Pokushalov, were presented for the first time at the 2017 AF Symposium by Professor Karl-Heinz Kuck, Head of the Department of Cardiology at the Asklepios Klinik in Hamburg, Germany. The presentation, “DURABLE-I Study: Real-time gap detection during AF ablation using dielectric sensing”, […]

Read more

FIX-HF-5C Late-Breaking Clinical Trial Data Presented at HRS 2018 with Simultaneous Publication in the JACC: Heart Failure

Orangeburg, New York, May 10, 2018

Impulse Dynamics (USA), Inc. announced results from its FIX-HF-5C randomized, Controlled Trial of Cardiac Contractility Modulation in Heart Failure.

Read more

The CFDA Approves Impulse Dynamics’ Optimizer System for Treatment of Chronic Heart Failure in China

Orangeburg, New York & Stuttgart, Germany. December 18, 2017

The China Food and Drug Administration (CFDA) has approved Impulse Dynamics’ Optimizer® system for treatment of chronic heart failure.  The announcement was made on December 12, 2017 by Impulse Dynamics’ CEO, Dr. Simos Kedikoglou.  “This is a major milestone for Impulse Dynamics, as it will help us offer Cardiac Contractility Modulation therapy to many patients […]

Read more

Impulse Dynamics Completes $45 million Financing Round

Stuttgart, Germany, May 11, 2017

Impulse Dynamics, developer of the revolutionary Cardiac Contractility Modulation (CCM) technology for treatment of Chronic Heart Failure (CHF), announced today that the company has closed a $45 million financing round…

Read more

Going red to raise awareness of heart disease in women

Mt. Laurel, New Jersey, February 3 2017

Friday February 3rd saw women and men across the United States dressed in shades of red, from scarlet to crimson, for National Wear Red Day.

Read more

Impulse Dynamics Successfully Launches the Optimizer Smart Device for Heart Failure Treatment in Europe

Stuttgart, Germany, November 15 2016

Impulse Dynamics has launched the next generation of its Optimizer device, the Optimizer Smart, in Europe after it received the CE mark. The Optimizer Smart is a minimally invasive implantable device designed to treat chronic heart failure (CHF) in patients that are symptomatic despite appropriate medical therapy…

Read more

Motorika and ORIGIN Polska Launch New Strategic Partnership to Enhance Rehabilitation Care in Poland

Hamilton, Bermuda, August 13, 2018

Motorika’s cutting-edge robotic rehabilitation solutions to be installed in ORIGIN Polska’s state-of-the-art rehab centers in Poland.

Read more

FIX-HF-5C Late-Breaking Clinical Trial Data Presented at HRS 2018 with Simultaneous Publication in the JACC: Heart Failure

Orangeburg, New York, May 10, 2018

Impulse Dynamics (USA), Inc. announced results from its FIX-HF-5C randomized, Controlled Trial of Cardiac Contractility Modulation in Heart Failure.

Read more

EPD obtains European regulatory approval for its Cardiac Mapping and Navigation System

Tortola, BVI, February 26, 2018

EPD’s Cardiac Mapping and Navigation System received CE mark approval.  The system helps electrophysiologists navigate the heart by generating an accurate 3D map, while imaging and pinpointing the exact location and orientation of catheters in the heart during diagnostic and therapeutic procedures for cardiac arrhythmias. “Receiving the CE mark is a very significant milestone for […]

Read more

The CFDA Approves Impulse Dynamics’ Optimizer System for Treatment of Chronic Heart Failure in China

Orangeburg, New York & Stuttgart, Germany. December 18, 2017

The China Food and Drug Administration (CFDA) has approved Impulse Dynamics’ Optimizer® system for treatment of chronic heart failure.  The announcement was made on December 12, 2017 by Impulse Dynamics’ CEO, Dr. Simos Kedikoglou.  “This is a major milestone for Impulse Dynamics, as it will help us offer Cardiac Contractility Modulation therapy to many patients […]

Read more

Impulse Dynamics Announces First US Implant in the FIX-HF-5CA Continued Access Study

Orangeburg, New York. August 8, 2017

Impulse Dynamics announced today the first implant in the Company’s FIX-HF-5CA Continued Access Study. The FIX-HF-5CA study is a multicenter, prospective, single-arm continued access evaluation of the company’s Cardiac Contractility Modulation (CCM) device. Impulse Dynamics’ proprietary CCM technology delivers non-excitatory electric pulses to the cardiac muscle, with the potential for improved exercise capacity and quality of life.

Read more

Impulse Dynamics Completes $45 million Financing Round

Stuttgart, Germany, May 11, 2017

Impulse Dynamics, developer of the revolutionary Cardiac Contractility Modulation (CCM) technology for treatment of Chronic Heart Failure (CHF), announced today that the company has closed a $45 million financing round…

Read more

Randomization of the FIX-HF-5C Confirmatory Study Completed

Orangeburg, New York, March 31, 2017

Impulse Dynamics is pleased to announce that it has successfully completed enrollment of the 160 subjects required for its FIX-HF-5C Confirmatory Study. The FIX-HF-5C Study is a prospective, multicenter, randomized study to evaluate the safety and efficacy of cardiac contractility modulation (CCM) signals delivered by the implantable Optimizer System in patients with NYHA class III […]

Read more

Going red to raise awareness of heart disease in women

Mt. Laurel, New Jersey, February 3 2017

Friday February 3rd saw women and men across the United States dressed in shades of red, from scarlet to crimson, for National Wear Red Day.

Read more

DURABLE-I ground-breaking clinical study results presented at the 2017 AF Symposium

Orlando, January 31 2017

Results from EPD’s DURABLE-I clinical trial, whose principal investigator is Professor Evgeny A Pokushalov, were presented for the first time at the 2017 AF Symposium by Professor Karl-Heinz Kuck, Head of the Department of Cardiology at the Asklepios Klinik in Hamburg, Germany. The presentation, “DURABLE-I Study: Real-time gap detection during AF ablation using dielectric sensing”, […]

Read more

Impulse Dynamics Successfully Launches the Optimizer Smart Device for Heart Failure Treatment in Europe

Stuttgart, Germany, November 15 2016

Impulse Dynamics has launched the next generation of its Optimizer device, the Optimizer Smart, in Europe after it received the CE mark. The Optimizer Smart is a minimally invasive implantable device designed to treat chronic heart failure (CHF) in patients that are symptomatic despite appropriate medical therapy…

Read more

About Hobart Group

The Hobart Group develops and commercializes medical technologies which target top healthcare markets with significant unmet needs.  Its growing portfolio of companies covers the areas of cardiology, diabetes, oncology, neurology and rehabilitation.  Together, Hobart Group companies have over 200 scientists, engineers, regulatory and business experts across four continents, benefitting from clinical expertise and extensive regulatory and international market knowledge across Europe, the USA and Asia.  For more information, visit www.Hobart-Group.com.

Media kit

Journalists and reporters are welcome to use the following materials related to Hobart Group

For media inquiries

Mrs. Sharon Alon
Email: Media@Hobart-Group.com
Tel: +1 347-566-6113

Stay up to date